GNTA
Genenta Science SPA
$
3.562
- Overview
- Forecast
- Valuation
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.6908
Open
3.360
VWAP
3.45
Vol
2.42K
Mkt Cap
65.15M
Low
3.360
Amount
8.36K
EV/EBITDA(TTM)
--
Total Shares
18.22M
EV
54.50M
EV/OCF(TTM)
--
P/S(TTM)
--
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune ...Show More
Valuation Metrics
The current forward P/E ratio for Genenta Science SPA (GNTA.O) is -4.49, compared to its 5-year average forward P/E of -9.84. For a more detailed relative valuation and DCF analysis to assess Genenta Science SPA 's fair value, click here.
Forward PE
N/A
5Y Average PE
-9.84
Current PE
-4.49
Overvalued PE
-4.08
Undervalued PE
-15.61
Forward EV/EBITDA
N/A
5Y Average EV/EBITDA
-5.79
Current EV/EBITDA
-1.59
Overvalued EV/EBITDA
-0.35
Undervalued EV/EBITDA
-11.22
Forward PS
N/A
5Y Average PS
31.96
Current PS
0.00
Overvalued PS
96.58
Undervalued PS
-32.66
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GNTA News & Events
Events Timeline
2025-03-19 (ET)
2025-03-19
09:31:57
Genenta Science announces EUR 20M financing to expand pipeline
2025-01-09 (ET)
2025-01-09
05:46:06
Genenta Science announces amendment to pact with AGC Biologics
2024-10-02 (ET)
2024-10-02
06:35:48
Genenta Science secures approval for trial for metastatic Renal Cell Cancer
News
7.5
01-09NewsfilterGenenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
1.0
01-08NewsfilterITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE
1.0
01-08PRnewswireITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE
8.5
2024-12-20Business InsiderGenenta Science Updates ATM Sales Agreement with New Agent
1.0
2024-10-23NewsfilterGenenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective"
4.0
2024-10-02BenzingaHC Wainwright & Co. Reiterates Buy on Genenta Science, Maintains $25 Price Target
-.-
2024-05-06newsfilterGenenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
-.-
2024-02-07businesswireGenenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
-.-
2023-09-05globenewswireGenenta to Present at Upcoming Scientific and Investor Conferences
-.-
2023-07-27globenewswireGenenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
-.-
2023-06-28globenewswireThe European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
-.-
2023-05-15globenewswireGenenta to Provide Update on Lead Product Temferon™
-.-
2023-04-25globenewswireGenenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
-.-
2023-04-02globenewswireGenenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications
-.-
2023-03-01globenewswireFDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme
-.-
2023-02-06globenewswireGenenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement
-.-
2022-11-07globenewswireGenenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients
-.-
2022-10-23globenewswireGenenta Provides First Half 2022 Business Update and Financial Results
-.-
2022-10-05globenewswireGenenta to Present at Upcoming Scientific and Investor Conferences
-.-
2022-09-06globenewswireGenenta to Present at Upcoming Investor Conferences
People Also Watch
ALX
Alexander's Inc
193.540
USD
-1.68%
TRS
TriMas Corp
19.900
USD
-2.74%
BBAI
BigBear.ai Holdings Inc
2.660
USD
-9.22%
FWRD
Forward Air Corp
10.500
USD
-15.66%
EH
EHang Holdings Ltd
15.410
USD
-7.11%
RDW
Redwire Corp
7.710
USD
-1.78%
GOOS
Canada Goose Holdings Inc
6.880
USD
-6.14%
SEAT
Vivid Seats Inc
2.450
USD
-1.61%
PHVS
Pharvaris NV
11.830
USD
-10.45%
GRC
Gorman-Rupp Co
31.360
USD
-2.03%
FAQ
What is Genenta Science SPA (GNTA) stock price today?
The current price of GNTA is 3.562 USD — it has increased 2.06 % in the last trading day.
What is Genenta Science SPA (GNTA)'s business?
What is the price predicton of GNTA Stock?
What is Genenta Science SPA (GNTA)'s revenue for the last quarter?
What is Genenta Science SPA (GNTA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Genenta Science SPA (GNTA)'s fundamentals?
How many employees does Genenta Science SPA (GNTA). have?